Skip to Content
BiomedicinesBiomedicines
  • Article
  • Open Access

20 November 2026

26 Pages

Biological Characterization and Pilot Clinical Evaluation of Growth Factor-Loaded Biosomes for Skin Regeneration

,
,
,
,
,
,
and
1
Cellese Inc., Irvine, CA 92606, USA
2
YH Science & Beauty, 120 E 56th St, 800, Floor 8, New York, NY 10022, USA
3
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, VIC 3053, Australia
*
Author to whom correspondence should be addressed.
Biomedicines2026, 14(11), 2703;https://doi.org/10.3390/biomedicines14112703 
(registering DOI)
This article belongs to the Section Nanomedicine and Nanobiology

Abstract

Background/Objectives: Extracellular vesicles (EVs) play a critical role in cell-to-cell communication and tissue homeostasis. Biosomes are lipid-based nanoparticles engineered with a defined bioactive protein cargo and a reproducible manufacturing process. The formulation was developed as an EV-inspired delivery platform designed to facilitate topical delivery of bioactive factors. This study evaluated the biological activity and clinical performance of Biosomes as a topical adjuvant to radiofrequency (RF) microneedling using in vitro, ex vivo, and clinical models of skin regeneration. Methods: Biosomes were characterized for physicochemical properties and assessed for cellular uptake in human dermal fibroblasts. In vitro studies evaluated cellular reductive activity, extracellular matrix (ECM) gene expression, collagen and hyaluronan production, and NF-κB signaling. Ex vivo 3D human skin models were treated for 7 days and analyzed for epidermal structure, loricrin expression, and collagen IV deposition. Clinical performance was evaluated in a randomized, investigator-blinded, placebo-controlled study of participants undergoing facial RF microneedling, with 25 participants completing the study through Day 60. Participants received either a Biosome-containing regimen or a control regimen immediately following treatment. Outcomes included investigator-rated Global Aesthetic Improvement Scale (GAIS) scores, VISIA imaging, participant-reported outcomes, and safety assessments. Results: Biosomes demonstrated consistent physicochemical characteristics across production batches and efficient cellular uptake. In vitro, Biosomes increased fibroblast cellular reductive activity, enhanced ECM-related gene expression, increased collagen and hyaluronan production, and reduced NF-κB signaling. Ex vivo treatment preserved epidermal architecture, increased loricrin expression, and enhanced collagen IV deposition at the dermal–epidermal junction. Clinically, the Biosome-containing treatment protocol was associated with significantly greater investigator-rated aesthetic improvement at Day 60 compared with the control group (GAIS, p = 0.0193), with trends in erythema recovery and other skin quality measures. The Biosome-containing regimen was generally tolerated throughout the study, and no treatment-related adverse events were reported. Conclusions: Biosomes demonstrated biological activity across in vitro, ex vivo, and clinical models, supporting epidermal differentiation, basement membrane organization, and skin recovery following RF microneedling. These findings support the potential utility of Biosomes as a topical regenerative adjunct to aesthetic procedures.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.